• 1
    Stupp R,Mason WP,van den Bent MJ, et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med. 2005; 352: 987996.
  • 2
    de Wit MC,de Bruin HG,Eijkenboom W,Sillevis Smitt PA,van den Bent MJ. Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression. Neurology. 2004; 63: 535537.
  • 3
    Brandes AA,Franceschi E,Tosoni A, et al. MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol. 2008; 26: 21922197.
  • 4
    Macdonald DR,Cascino TL,Schold SCJr,Cairncross JG. Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol. 1990; 8: 12771280.
  • 5
    Griebel M,Friedman HS,Halperin EC, et al. Reversible neurotoxicity following hyperfractionated radiation therapy of brain stem glioma. Med Pediatr Oncol. 1991; 19: 182186.
  • 6
    Chamberlain MC,Glantz MJ,Chalmers L,Van Horn A,Sloan AE. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol. 2007; 82: 8183.
  • 7
    Chakravarti A,Erkkinen MG,Nestler U, et al. Temozolomide-mediated radiation enhancement in glioblastoma: a report on underlying mechanisms. Clin Cancer Res. 2006; 12: 47384746.
  • 8
    Ruben JD,Dally M,Bailey M,Smith R,McLean CA,Fedele P. Cerebral radiation necrosis: incidence, outcomes, and risk factors with emphasis on radiation parameters and chemotherapy. Int J Radiat Oncol Biol Phys. 2006; 65: 499508.
  • 9
    Ballman KV,Buckner JC,Brown PD, et al. The relationship between 6-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme. Neuro Oncol. 2007; 9: 2938.
  • 10
    Zeng QS,Li CF,Liu H,Zhen JH,Feng DC. Distinction between recurrent glioma and radiation injury using magnetic resonance spectroscopy in combination with diffusion-weighted imaging. Int J Radiat Oncol Biol Phys. 2007; 68: 151158.